NCT04853758View on ClinicalTrials.gov

Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.

PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2024

Conditions
Chagas Cardiomyopathy
Interventions
DRUG

Sacubitril / Valsartan Oral Tablet [Entresto]

100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive sacubitril/valsartan for 6 months.

DRUG

Enalapril

100 consecutive participants randomized independently at the Heart Institute - School of Medicine of the University of São Paulo (InCor),will receive enalapril for 6 months.

Trial Locations (1)

05403000

RECRUITING

Heart Institute (Incor) University of Sao Paulo, São Paulo

All Listed Sponsors
collaborator

InCor Heart Institute

OTHER

lead

University of Sao Paulo General Hospital

OTHER